

September 1, 2020

**British Columbia  
Securities  
Commission**  
701 West Georgia  
Street  
Vancouver, BC  
V7Y 1L2

**Alberta  
Securities  
Commission**  
250 5<sup>th</sup> Street  
West  
Calgary, AB  
T2P 0R4

**Saskatchewan  
Securities  
Commission**  
1919 Saskatchewan  
Drive  
Regina, SK  
S4P 4H2

**Ontario  
Securities  
Commission**  
5251 Duke  
Street  
Halifax, NS  
B3J 1P3

**Canadian  
Securities  
Exchange**  
100 King Street  
West  
Toronto, ON  
M5X 1E1

Dear Sirs/Mesdames:

**Re: HAVN Research Inc. (the “Company”).**

We refer to the non-offering prospectus of HAVN Life Sciences Inc. (“HAVN Life Sciences”) dated September 1, 2020, relating to the qualification for distribution of 33,906,667 common shares of HAVN Life Sciences, issuable for no additional consideration upon the deemed exercise of 33,906,667 special warrants of HAVN Life Sciences (at \$0.02 per special warrant), and the qualification for distribution of 249,000 common shares of HAVN Life Sciences, issuable for no additional consideration upon the deemed exercise of 249,000 special warrants of HAVN Life Sciences (at \$0.10 per special warrant).

We consent to being named and to the use, in the above-mentioned prospectus, of our report dated September 1, 2020 to the directors of the Company on the following financial statements:

- Statement of financial position as at April 30, 2020; and
- Statements of loss and comprehensive loss, changes in shareholders’ equity and cash flows for the period from incorporation on March 4, 2020 to April 30, 2020, and a summary of significant accounting policies and other explanatory information.

We report that we have read the prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the above financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor’s consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,



**CHARTERED PROFESSIONAL ACCOUNTANTS**